Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wont get a response.May be, is stuck just like me.
And what merger you are talking about?
This is for LHHMQ and we are in LEHNQ.Why the claims are not EXPUNGED?
Why the CT claims are allowed and not expunged?.Dont they have to Expunge the claims inorder to cancel the securities?.
Classes 3 to 5 need to be satisfied 100% inorder to get any distributions to classes 10A,10B and 10C.
Record date May 18 2016?
Why did they set a record date for the distribution s on June 16?
Are the claims still trading?.
Are these claims CTs?
I did not send any forms for Cts as aquired them after the plan approval.I sent some information for my JQs and DQs.
I do own Nqs,Kqs,Jqs.
If i dont own any, why would i even be on this forum?.
JPM Getting around 1.49B in 10th distribution, does CTs get any thing?.
Did any of CT holders complete OFAC and tax forms?
http://www.businesswire.com/news/home/20160609005612/en
cGMP was one of those milestones as per the below press release
Dec 22,2015
Amarantus Provides Update on cGMP Manufacturing Validation for the Engineered Skin Substitute (ESS) Program
SAN FRANCISCO, Dec. 22, 2015 /PRNewswire/ -- Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today provided an update on the status of its current manufacturing process validation for producing ESS at Lonza Walkersville, a premier contract manufacturer providing cell- and tissue-based products for clinical development. Ongoing engineering run activities are progressing successfully, and Amarantus expects to complete the necessary steps to confirm the process in January. Upon completing the validation studies, Amarantus will be ready from the operational perspective to open the planned Phase 2 clinical study for the treatment of full thickness thermal burns covering over 50% of the body. The trial is being conducted under a Collaborative Research & Development Agreement (CRADA) with the U.S. Army at the Institute for Surgical Research at Fort Sam Houston in Texas.
Milestones towards validation are as follows:
Aseptic process simulation execution and qualification of the process and personnel used in manufacturing:
Completed in November 2015
Initial engineering run whereby autologous full thickness skin from an adult human donor is produced:
Completed in December 2015
Confirmatory engineering run whereby autologous full thickness skin from an adult human donor is produced:
In progress - Expected completion in January 2016
"Validating the manufacturing process for ESS is the key operational milestone at this point on the program's path towards commercialization," said Gerald E. Commissiong, President & CEO of Amarantus. "Working with an established contract manufacturer, we will be operationally enabled to open up the 10 patient Phase 2 clinical study under our CRADA with the US Army's ISR, and we will also be in a position to initiate discussions with the FDA on trial designs for evaluating ESS in Giant Congenital Melanocytic Nevi (GCMN) and pediatric severe burn indications. We believe ESS may be eligible to achieve Rare Pediatric Disease Designation (RPDD) for both of these indications, and our regulatory team is now focused on submitting the request for RPDD for the treatment of GCMN to the U.S. FDA by the end of 2015, with a decision in the first quarter of 2016. Given that it is estimated GCMN affects a very small pediatric population, (between 8 and 80 newborns annually in the U.S), we anticipate a potentially rapid product approval pathway with the pivotal program anticipated to initiate in the second half of 2016."
The FDA defines a "rare pediatric disease" as a disease that affects fewer than 200,000 individuals in the U.S. primarily aged from birth to 18 years. Under the FDA's Rare Pediatric Disease Designation (RPDD) Priority Review Voucher (PRV) program, a sponsor who receives an approval of a new drug application (NDA) or biologics license application (BLA) for a rare pediatric disease may be eligible for a voucher, which can be redeemed to obtain expedited FDA review for any subsequent marketing application. The PRV may be sold or transferred by the recipient. The two most recent PRVs that were sold garnered a combined $595M in cash from Sanofi and Abbvie.
About Giant Congenital Melanocytic Nevus
Giant Congenital Melanocytic Nevus, a rare pediatric condition (also known as "Bathing trunk nevus," "Garment nevus," "Giant hairy nevus", and "Nevus pigmentosus et pilosus"), is defined by one or more large, darkly pigmented and sometimes hairy patches. The congenital (present at birth) melanocytic nevus appears as a circumscribed, light brown to black patch, potentially varying in consistency, covering any size surface area and any part of the body. As compared with melanocytic nevi that arise after birth, congenital melanocytic nevi are usually larger in diameter and may have excess hair, a condition called hypertrichosis. The estimated prevalence for the largest melanocytic nevi is 0.002% of births in the US. A serious risk factor for the largest CMN concerns the incidence of melanoma, which can be up to 10%. Generally, melanoma in patients with large to giant CMN occurs within the first decade of life with the greatest incidence rate before age 5 and has a high fatality rate. A second life-threatening complication of the larger forms of CMN is neurocutaneous melanocytosis (NCM), a neurological and dermatological disorder characterized by abnormal cellular aggregations within the central nervous system and the skin. The incidence of NCM ranges between 5 and 15 % in this CMN patient subset; death usually occurs within 2-3 years of diagnosis of symptomatic NCM.
About Engineered Skin Substitute (ESS)
Engineered Skin Substitute (ESS) is a tissue-engineered skin prepared from autologous (patient's own) skin cells. It is a combination of cultured epithelium with a collagen-fibroblast implant that produces a skin substitute that contains both epidermal and dermal components. This model has been shown in preclinical studies to generate a functional skin barrier. Most importantly, because ESS is composed of a patient's own cells, it is less likely to be rejected by the immune system of the patient, unlike with porcine or cadaver grafts in which immune system rejection is a possibility. ESS has been used in an investigator initiated clinical setting in over 130 human subjects, primarily pediatric patients, for the treatment of severe burns up to 95% total body surface area.
June 07,2016
Amarantus Announces cGMP Manufacturing Readiness for Its Engineered Skin Substitute (ESS) Program at Lonza Walkersville
Amarantus-sponsored training for Phase 2 severe burn trial completed with U.S. Army clinical site in late April
SAN FRANCISCO, June 7, 2016 /PRNewswire/ --
Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that the current Good Manufacturing Practices (cGMP) manufacturing process for its Engineered Skin Substitute (ESS) program is now qualified at Lonza Walkersville, Inc., a premier contract manufacturer providing cell and tissue-based products for clinical development. ESS is a lab-grown, full-thickness skin graft made from a patient's own skin that is expanded ~100 fold in size to provide permanent wound coverage of large body surface areas, initially for use in treating life-threatening burns.
Reaching this milestone signifies that Amarantus is now positioned to supply ESS for its planned opening of the 10-patient, randomized, placebo-controlled, open-label Phase 2 clinical trial for the treatment of adult patients (ages 18-40 years old) with deep-partial and full-thickness thermal burns covering ≥50% of total body surface area (TBSA). The Company will open enrollment at the first site, the U.S. Army's Institute for Surgical Research (ISR) at Fort Sam Houston in Texas, under a Collaborative Research & Development Agreement (CRADA). Two additional civilian sites will be opened after ISR to accelerate enrollment of the study.
The Phase 2 clinical trial is designed to measure the safety and comparability of ESS with meshed split-thickness autografted skin, the current standard of care in the treatment of life-threatening severe burns. Amarantus will be reporting pre-defined data points on an ongoing basis throughout the trial on a patient-by-patient basis.
"cGMP-readiness at Lonza marks the first of several major milestones for the ESS program," said Gerald E. Commissiong, President & CEO of Amarantus. "Amarantus performed the sponsor portion of the site initiation process at ISR in late April, and the site is completing its final preparations to initiate the study. We expect the remaining items to be completed soon, at which point we will open enrollment for this breakthrough regenerative medicine cell therapy trial at the US Army's premier surgical research center."
About Engineered Skin Substitute (ESS)
Engineered Skin Substitute (ESS) is a tissue-engineered skin prepared from autologous (patient's own) skin cells. It is a combination of cultured epithelium with a collagen-fibroblast implant that produces a skin substitute that contains both epidermal and dermal components. This model has been shown in preclinical studies to generate a functional skin barrier. Most importantly, because ESS is composed of a patient's own cells, it is less likely to be rejected by the immune system of the patient, unlike with porcine or cadaver grafts in which immune system rejection is a possibility. A non-GMP version ESS has been used in investigator-initiated and compassionate-use clinical settings in over 150 human subjects, primarily pediatric patients, for the treatment of severe burns up to 95% of total body surface area. The non-GMP version has also been used in the treatment of two patients with Giant Congenital Melanocytic Nevi (GCMN). The Company is evaluating opportunities to launch a pivotal clinical study with ESS in the areas of GCMN and pediatric severe burns once experience is gained in the adult severe burn setting.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases. AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture. ESS is entering Phase 2 clinical studies under a CRADA agreement with the US Army. AMBS has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression, and owns the intellectual property rights to a therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF) and is developing MANF-based products as treatments for brain and ophthalmic disorders. MANF was discovered from the Company's proprietary discovery engine PhenoGuard. AMBS also received 80 million shares of Avant Diagnostics, Inc. via the sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc.
Why would he do if he also part of the scheme?
Fiduciary Duties
Both the board of directors and the CEO of a small business have a fiduciary responsibility to the business's shareholders. The fiduciary duties are legal concepts that form the basis of a CEO's legal relationship with his company's owners. According to the American Bar Association, courts have ruled that a CEO's relationship with his small business's shareholders carries more legal responsibility than his relationship with his company's creditors. This is because the creditors' relationship with the company exists purely as a result of a legal contract. The shareholders' relationship with the CEO, by contrast, entails both a binding contract and the trust of that CEO in controlling the shareholders' property.
Duties of Care, Loyalty and Disclosure
A CEO's legal responsibilities to his company's shareholders are broken down into three distinct fiduciary duties: the duty of care, the duty of loyalty and the duty of disclosure. The duty of care refers to the CEO's responsibility to consider all of the available information relevant to business decisions, including the advice of experts and employees. The duty of care also includes the responsibility to understand and evaluate the company's day to day operations and the terms of agreements. The duty of loyalty requires that a CEO always acts in the best interest of a business's shareholders, and that he places that interest above his own in business decisions. This includes the responsibility to avoid conflicts of interest. Finally, the fiduciary duty of disclosure mandates that a CEO fully inform both the board of directors and the shareholders about the major issues facing the business.
0.06 the reason being...
$ / shares
Debt Instrument [Line Items]
Stated Interest Rate
12.00%
Conversion Terms | $ / shares
$ 0.05
Accumulated Debt Discount
$ (2,963)
Carrying Value
$ 2,389
Delafeild Investments Ltd [Member] | Senior Secured Convertible Promissory Notes [Member]
Debt Instrument [Line Items]
Issue Date
Sep. 30, 2015
Maturity Date
Sep. 29, 2016
Stated Interest Rate
12.00%
Conversion Terms | $ / shares
$ 0.06
Face Value
$ 3,056
Accumulated Debt Discount
(1,716)
Carrying Value
$ 1,340
Dominion Capital LLC [Member] | Senior Secured Convertible Promissory Notes [Member]
Debt Instrument [Line Items]
Issue Date
Sep. 30, 2015
Maturity Date
Sep. 29, 2016
Stated Interest Rate
12.00%
Conversion Terms | $ / shares
$ 0.06
Face Value
$ 2,096
Accumulated Debt Discount
(1,177)
Carrying Value
$ 919
GEMG LLC [Member] | Senior Secured Convertible Promissory Notes [Member]
Debt Instrument [Line Items]
Issue Date
Mar. 09, 2016
Maturity Date
Jul. 01, 2016
Stated Interest Rate
12.00%
Conversion Terms | $ / shares
$ 0.06
Face Value
$ 200
Accumulated Debt Discount
(70)
Carrying Value
$ 130
Why do you think AMBS applied for RPDD for ESS ,Nevus and Elto?.
Why do you think AMBS hired Dr.Brian Harvey?
He did the RS showing uplisting as a cause, TFs and his backdoor allies shorted all the way thru 0.029 .Now planned to RS again, to do the same again, but looks like hesitating to do that.
This CEO is irresponsible and not working in the best interests of shareholders.He agreed to short the shares as a hedge, great work of srff.The only miracle is approval of RPDD for ESS and Elto,imho.
They defaulted on the notes terms and hence conversions, imho.Dont mislead.
As otcqb certification
shares owned by GC and others.
Name
Address (City and State only)
% Shares Owned
Gerald Commissiong
Hummelstown, PA
0.15
John Commissiong
Sunnyvale, CA
0.19
Robert Harris
Oakland, CA
0.21
Joseph Rubinfeld
Blackhawk, CA
0.04
Robert Farrell
Novato, CA
0.00
Marc Faerber
Pleasanton, CA
0.01
Date: 6/6/2016
Name of Certifying CEO or CFO: Gerald Commissiong
Title: CEO
This company has IP which is not valued.But it bought the ESS and other products and raised around $40mm last year.That value should be there,though the stock price does not reflect it yet.
Biotech success stories does not happen in months, it takes time for the research and clinical trials.Its not a day trade stock imho.
Are you holding stock or buying or selling?.Are you trying to help fellow shareholders like me?.
P&A dictates the POR and GSA.Assets were transferred/assigned to JPM and WMI according to 363 sales in chapter 11.Initial payment was made of 1.9B, the final amount should be settled at the final closing date, that should happen some time soon,imho. Who saved who, is not relevant.
Do you have any court document where JPM mentioned seizing the bank was in the best interests of WMILT?
Why are you telling us?
JPM says it is in the best interest of WMILT and other parties in interest.Looks like they have to finalize the payments,imho.When and how much....based on P&A agreement...may be book value times 3, fair and reasonable.
In the best interest of WMILT and all parties in interest
Payments soon from WMILT to former shareholders?
http://www.kccllc.net/wamu/document/list/3853
Docket # 12260 , page 2
Who bought the "dump" ?
11mm vapored and bod is so happy to talk about but hiding behind confidentiality agreements?.Did any one ask when do the shorting period starts?.
ESS is entering Phase 2 clinical studies under a CRADA agreement with the US Army.Nice to know that.
It says ITS ONGOING as per the clinicaltrials website.
ESS prize? No one knows what this means.
Elto is active
This study is ongoing, but not recruiting participants.
https://clinicaltrials.gov/ct2/show/study/NCT02439125?term=eltoprazine&rank=2
Can collectively write to THJMW on escrow shares
If some leader organizes a decent letter requesting the court to answer on escrow shares, i can sign in along with other 1000s of shareholders.
From Jon Goulding declaration:
Section 1123(b)(6). Article XXXVIII of the Seventh Amended Plan provides that the
Court will retain jurisdiction as to, among other things, all matters involving the
Seventh Amended Plan, the claims allowance and distribution process, and the
prosecution of claims and causes of action. Accordingly, the continuing jurisdiction
of the Court is consistent with applicable law and permissible under section
1123(b)(6) of the Bankruptcy Code.
So what happens to the shares held by them? Does it benefit them if the share price increase or decrease?
yeah what do they do?
What do the institutions do with more than 60million shares held by them?
lol...who cares?.
There is no price set to purchase stock.It is at company's wish whether to sell in 500K units at different intervals or terminate the agreement.
I agree.I did too, but i was referring it due to the $20mm funding by Lincoln Park, it seems still valid thru August 2016.
My question is, why institutions like Lincoln Park still holding common shares if there is no value in it?
Where is the proxy for voting?
What is the ratio of reverse split?
When is the Registration filed?.Is there an IPO and uplist? or sale altogether and at what price?.
What is the status of RPDD for ESS?
Phase 3 clinical trial for ESS starting soon?
So many unknowns, value is there some where.
Do yourself a favor by reading 10-k filed yesterday with SEC
Now institutions own more common shares than ever before.
1.Through December 31, 2015, the Company has sold an additional 37,445,801 shares of common stock for gross proceeds of $2.8 million under its agreement with LPC.
Out of 67 million outstanding shares, imho more than 80% is held by institutions.
Is this not a good indication that there is some thing brewing up in a positive way to the common equity?
$20 Million funding
Lincoln Park Capital
In March 2014, we entered into an agreement with Lincoln Park Capital Fund LLC (“LPC”) for an equity financing agreement. LPC is obligated to purchase up to $20.0 million of the Company’s common stock from time to time over a 30 month period, in amounts up to $0.5 million per sale as directed by the Company and subject to certain requirements, restrictions and limitations. There are no upper limits to the price LPC may pay to purchase our common stock and the purchase price is based on prevailing market prices of our stock at the time of sales without any fixed discount, We control the timing and amount of any sales to LPC In addition, we may direct LPC to purchase additional amounts as accelerated purchases the closing price of our stock is not below certain threshold price. We filed a registration statement with the SEC covering the shares issuable to LPC. As of December 31, 2015, we had approximately $17.3 million available to us under the agreement.
Through December 31, 2015, the Company has sold an additional 37,445,801 shares of common stock for gross proceeds of $2.8 million under its agreement with LPC.
Common stock private placement
-------------------------------
In March 2014, the Company entered into an equity financing agreement (“LPC Purchase Agreement”) with Lincoln Park Capital Fund LLC (“LPC”) whereby LPC is obligated to purchase up to $20.0 million of the Company’s common stock from time to time over a 30 month period, as directed by the Company and subject to certain requirements, restrictions and limitations. Under the LPC Purchase Agreement, the per share purchase price will be the lesser of the lowest sale price of common stock on the purchase date or the average of the three lowest closing purchase prices during the ten consecutive business days prior to the purchase date. However, LPC is not obligated to purchase shares from the Company on any date that the closing price of the common stock is below $6.00, subject to adjustment upon the occurrence of certain stock related events. The Company may also request that LPC purchase shares under an accelerated purchase notice whereby the per share purchase price will be the lower of (i) 94% of a volume weighted average price calculation as determined under the LPC Purchase Agreement or (ii) the closing price of the common stock on the accelerated purchase date.
Concurrently with the execution of the LPC Purchase Agreement, LPC purchased an initial 26,667 shares for gross proceeds of $0.4 million.
In consideration for entering into the LPC Purchase Agreement, the Company issued 63,333 shares of common stock to LPC (the ‘Commitment Fee Shares’), 40,000 upon entering into the agreement and 23,333 contingently issuable on a pro rata basis as the Company utilizes the financing arrangement. The agreement will automatically terminate upon the earlier of 30 months (August 2016) or upon full utilization of the purchase commitment.
The fair value of the 40,000 Commitment Fee Shares initially issued to LPC was approximately $0.5 million at issue and initially recorded as a deferred funding fee asset. The fee, as well as fair value at issue of subsequent Commitment Fee Shares, has been recognized as additional paid in capital as of December 31, 2014.
During the first quarter of 2015 under the Lincoln Park Capital Fund LLC financing arrangement the Company sold 256,305 common shares and issued 3,290 common shares as a commitment fee for a total of $2.8 million.